NCT01601119

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 545 (actual)
• Sponsor: Merck KGaA, Darmstadt, Germany · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

Conditions

• Relapsing Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Rebif	The subjects will receive Rebif as per the current practices or as directed by the physician.
OTHER	Other: Disease modifying therapies (DMT)	The subjects will receive other DMTs as per the current practices or as directed by the physician.

Timeline

• Start date: 2012-01-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2012-05-17
• Last updated: 2015-05-29

Locations

1 site across 1 country: United Kingdom